Ripasudil
- Generic Name
- Ripasudil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C15H18FN3O2S
- CAS Number
- 223645-67-8
- Unique Ingredient Identifier
- 11978226XX
- Background
Ripasudil, as hydrochloride hydrate (K-115), is a specifc Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor used for the treatment of glaucoma and ocular hypertension. It was first approved for treatment in Japan in September 2014. This medication is available in the form of a 0.4% eye drop solution under the brand name Glanatec. Ripasudi...
- Indication
Ripasudil has been proven to be effective in the twice daily treatment of glaucoma and ocular hypertension. It is currently in studies to be approved for both diabetic retinopathy and diabetic macular oedema.
- Associated Conditions
- Ocular Hypertension, Open Angle Glaucoma (OAG)
- Associated Therapies
- -
The Effects of Ripasudil in Patients With FED Undergoing Femtosecond Laser Assisted Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-09-21
- Last Posted Date
- 2023-09-21
- Lead Sponsor
- Singapore Eye Research Institute
- Target Recruit Count
- 120
- Registration Number
- NCT06048380
- Locations
- 🇸🇬
Singapore National Eye Centre, Singapore, Singapore
A Study to Investigate the Safety and Efficacy of K-321 Eye Drops After Simultaneous Cataract Surgery and Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
- Conditions
- Interventions
- First Posted Date
- 2023-04-24
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 110
- Registration Number
- NCT05826353
- Locations
- 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇺🇸Macy Eye Center, Los Angeles, California, United States
🇺🇸Byers Eye Institute at Stanford, Palo Alto, California, United States
A Study to Evaluate the Safety and Efficacy of K-321 Eye Drops After Descemetorhexis in Participants With Fuchs Endothelial Corneal Dystrophy (FECD)
- Conditions
- Interventions
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-10-29
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 100
- Registration Number
- NCT05795699
- Locations
- 🇺🇸
Keck Hospital of USC, Los Angeles, California, United States
🇺🇸Macy Eye Center, Los Angeles, California, United States
🇺🇸Jules Stein Eye Institute, Los Angeles, California, United States
Study to Assess Safety and Tolerability of Multiple Doses of EO2002
- First Posted Date
- 2022-12-05
- Last Posted Date
- 2024-08-02
- Lead Sponsor
- Asociación para Evitar la Ceguera en México
- Target Recruit Count
- 12
- Registration Number
- NCT05636579
- Locations
- 🇲🇽
Asociacion para Evitar la Ceguera en Mexico, Mexico City, Cdmx, Mexico
A Study to Investigate the Safety and Efficacy of Ripasudil (K-321) Eye Drops After Cataract Surgery
- Conditions
- Interventions
- First Posted Date
- 2022-09-06
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Kowa Research Institute, Inc.
- Target Recruit Count
- 331
- Registration Number
- NCT05528172
- Locations
- 🇺🇸
Eye Care Specialists, Kingston, Pennsylvania, United States
🇺🇸Center for Sight, Las Vegas, Nevada, United States
🇺🇸Houston Eye Associates, Houston, Texas, United States
Descemet Endothelial Thickness Comparison Trial II
- Conditions
- Interventions
- First Posted Date
- 2022-03-11
- Last Posted Date
- 2024-05-10
- Lead Sponsor
- Stanford University
- Target Recruit Count
- 60
- Registration Number
- NCT05275972
- Locations
- 🇺🇸
Stanford University, Palo Alto, California, United States
🇺🇸Oregon Health & Science University, Portland, Oregon, United States
🇺🇸University of Pennsylvania, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.